|257.74||+9.53||+3.84%||Vol 316.32K||1Y Perf -27.65%|
|Feb 2nd, 2023 12:03 DELAYED|
|- -%||- -|
|Target Price||283.25||Analyst Rating||Moderate Buy 1.55|
|Potential %||9.32||Finscreener Ranking||★★★ 49.88|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 49.11|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 58.41|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||45.33||Earnings Rating||Sell|
|Market Cap||13.11B||Earnings Date||15th Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||15th Feb 2023|
|Estimated EPS Next Report||2.75|
|EPS Growth Next 5 Years %||14.00|
|Avg. Weekly Volume||315.99K|
|Avg. Monthly Volume||469.36K|
|Avg. Quarterly Volume||592.88K|
Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 248.21 per share at the end of the most recent trading day (a 2.04% change compared to the prior day closing price) with a volume of 300.96K shares and market capitalization of 13.11B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.
The one-year performance of Charles River Laboratories International Inc. stock is -27.65%, while year-to-date (YTD) performance is 13.91%. CRL stock has a five-year performance of 141.12%. Its 52-week range is between 181.36 and 349.84, which gives CRL stock a 52-week price range ratio of 45.33%
Charles River Laboratories International Inc. currently has a PE ratio of 25.90, a price-to-book (PB) ratio of 4.26, a price-to-sale (PS) ratio of 4.03, a price to cashflow ratio of 18.40, a PEG ratio of 2.32, a ROA of 6.53%, a ROC of 8.04% and a ROE of 18.64%. The company’s profit margin is 10.55%, its EBITDA margin is 23.00%, and its revenue ttm is $2.88 Billion , which makes it $56.53 revenue per share.
Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.75 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is 15th Feb 2023.
The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Moderate Buy (1.55), with a target price of $283.25, which is +9.32% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Charles River Laboratories International Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.26, ATR14 : 7.99, CCI20 : 84.47, Chaikin Money Flow : 0.25, MACD : 5.94, Money Flow Index : 56.89, ROC : 6.70, RSI : 60.51, STOCH (14,3) : 77.55, STOCH RSI : 0.83, UO : 55.97, Williams %R : -22.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: David R. Smith (Option Excercise at a value of $1 224 594), David R. Smith (Sold 8 965 shares of value $2 532 920 ), George E. Massaro (Sold 148 shares of value $34 177 ), James C. Foster (Option Excercise at a value of $4 741 630), James C. Foster (Sold 57 407 shares of value $17 084 160 ), Joseph W. LaPlume (Option Excercise at a value of $766 181), Joseph W. LaPlume (Sold 9 077 shares of value $2 162 302 ), Michael Gunnar Knell (Option Excercise at a value of $93 486), Michael Gunnar Knell (Sold 855 shares of value $212 544 ), Richard F. Wallman (Buy at a value of $328 350), Richard F. Wallman (Sold 7 200 shares of value $2 108 413 ), Shannon M. Parisotto (Option Excercise at a value of $249 186), Shannon M. Parisotto (Sold 2 279 shares of value $569 522 ), William D. Barbo (Option Excercise at a value of $350 435), William D. Barbo (Sold 3 205 shares of value $704 814 )
Mon, 10 Oct 2022 14:24 GMT FDA Demands More Data for Supernus SPN-830 NDA Filing- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.